Utilising MYMEDS-CARDMET questionnaire in supporting medicines optimisation in post myocardial infarction patients with diabetes...Royal Pharmaceutical Society Annual Conference, November 7, 2025, London, United Kingdom

Alasmary,S.; Ajjan,R.; Wheatcroft,S. B.; Khatib,R.

Utilising MYMEDS-CARDMET questionnaire in supporting medicines optimisation in post myocardial infarction patients with diabetes...Royal Pharmaceutical Society Annual Conference, November 7, 2025, London, United Kingdom

All Authors

Alasmary,S.

Ajjan,R.

Wheatcroft,S. B.

Khatib,R.

LTHT Author

Alasmary, Sarah
Ajjan, Ramzi
Wheatcroft, Stephen
Khatib, Rani

LTHT Department

Cardio-Respiratory
Cardiology
Specialty & Integrated Medicine
Diabetes
Medicines Management & Pharmacy Services
Clinical Pharmacy

Non Medic

Consultant Pharmacist

Publication Date

2025

Item Type

Conference Abstract

Abstract

Introduction: Among post myocardial infarction (MI) patients with diabetes, adherence to diabetes medications is as significant as adherence to cardiovascular secondary prevention medications to reduce the risk of further major cardiovascular events 1,2]. Patient self-reporting is an effective method to assess adherence and address actual and potential barriers to adherence 3,4]. Aim: This evaluation aims to assess patients� experiences using the MYMEDS-CARDMET questionnaire by exploring potential barriers to medication adherence and evaluating knowledge of risk factors and targets for managing cardiovascular disease and diabetes. Methodology: The MYMEDS-CARDMET questionnaire was adapted from the published MYMEDS questionnaire 5]. Post MI patients who had diabetes were consecutively sent the MYMEDS-CARDMET to complete over 12 months period in 2022. The data was analysed retrospectively. As the data of MYMEDS-CARDMET was part of a service evaluation of development project for patients under the care of clinicians in the cardiology department at Leeds Teaching Hospitals NHS Trust (LTHT), no ethical approval was required. The data was extracted from Excel (version 2211) and the analysis was performed using Excel and SPSS (version 29). Results: The MYMEDS-CARDMET was completed by 95 post-MI patients with diabetes (72% NSTEMI, 73% males) with a mean age of 70.7�.6 (36�) years. Their concurrent diagnoses were type 2 DM (96%), type 1 DM (2%) or pre-diabetes (2%). Overall, 78 (82%) respondents had at least one potential barrier that is causing or could lead to non-adherence to cardiovascular or diabetes medicines. The most common barriers were as follows: being concerned about the quantity of medication prescribed (52%), being worried about medications� side effects (44%), being concerned that heart and diabetes medicines could cause more harm than good (31%), forgetting to take heart and diabetes medications (25%), followed by difficulties opening medicine bottles or blister packs (23%). Hearing or reading negative information about heart and diabetes medications in the media was reported to increase concerns by 32% of patients. When evaluating the levels of reported medicines nonadherence, 47 (49.5%) respondents reported non-adherent behaviour to at least one of the heart or diabetes medicines. The most common reason was forgetfulness, reported by 53% of non-adherents. There was more non-adherence to diabetes medications due to alterations. The highest level of non-adherence to cardiac medications was to lipid-lowering therapies and antiplatelets, while non-adherence to GLP-1 RA and sulphonylureas was most common among the diabetes medications. Respondents reported poor understanding and inadequate knowledge of their risk factors and corresponding targets (blood pressure, cholesterol, HaemglobinA1C, blood glucose level) which could potentially contribute to non-adherence. Discussion: The management of post-MI patients with diabetes should be approached holistically to improve patient outcomes. MYMEDS-CARDMET could potentially be an effective self-report tool for addressing potential barriers to medication non-adherence and better understanding of risk factors and targets. MYMEDS-CARDMET can be utilised by clinicians in cardiometabolic services to deliver a more personalised care plan, thereby addressing specific individual patient issues, improving adherence and ultimately clinical outcomes. Self-report tools, such as MYMEDS-CARDMET, could overestimate adherence due to social desirability; a limitation for this study.